http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 08:41:07 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Unicycive+Therapeutics+%28UNCY%29+PT+Raised+to+%2418+at+Benchmark/26587906.html (Updated - June 2, 2026 8:41 AM EDT) <p>Benchmark analyst Bruce Jackson raised the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $18.00 (from $15.00) while maintaining a Speculative Buy rating.</p><p>The analyst commented, "In January, the FDA accepted the company’s resubmission of a New Drug Application (NDA) for oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis and assigned a PDUFA date of June 29, 2026. As of May 11, 2026, Unicycive had an unaudited cash balance of $57.1 million in cash, cash equivalents, and short-term investments, which should fund operations into 2027 http://www.streetinsider.com/Analyst+PT+Change/Unicycive+Therapeutics+%28UNCY%29+PT+Raised+to+%2418+at+Benchmark/26587906.html Tue, 02 Jun 2026 08:41:07 -0400 UNCY http://www.streetinsider.com/Analyst+Comments/Unicycive+Therapeutics+%28UNCY%29+PT+Raised+to+%2418+at+Benchmark/26587906.html (Updated - June 2, 2026 8:41 AM EDT) <p>Benchmark analyst Bruce Jackson raised the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $18.00 (from $15.00) while maintaining a Speculative Buy rating.</p><p>The analyst commented, "In January, the FDA accepted the company’s resubmission of a New Drug Application (NDA) for oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis and assigned a PDUFA date of June 29, 2026. As of May 11, 2026, Unicycive had an unaudited cash balance of $57.1 million in cash, cash equivalents, and short-term investments, which should fund operations into 2027 http://www.streetinsider.com/Analyst+Comments/Unicycive+Therapeutics+%28UNCY%29+PT+Raised+to+%2418+at+Benchmark/26587906.html Tue, 02 Jun 2026 08:41:07 -0400 UNCY http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Unicycive+Therapeutics+%28UNCY%29/26553184.html <p>H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $22.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).</p><p>The analyst commented: "Unicycive relies on third-party manufacturers to produce its lead drug candidate, oxylanthanum carbonate (OLC), including its long-term manufacturing partner, Shilpa Medicare (SLPA.IN; not rated). Shilpa hosted an investor call and announced an additional NCE program commissioned for OLC that will be dedicated to the development for OLC, with validation batches expected to complete in 1Q FY2027 (quarter ending June 30, 2026). In June 2024, Unicycive amended its supply agreement with Shilpa, specifically to “provide certain funding to Shilpa for a http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Unicycive+Therapeutics+%28UNCY%29/26553184.html Wed, 27 May 2026 06:50:56 -0400 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Shalabh+K./26535923.html si-local-file:///var/storage/secattach/20260521/26535923.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Shalabh+K./26535923.html Thu, 21 May 2026 16:30:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Shalabh+K./26535923.html si-local-file:///var/storage/secattach/20260521/26535923.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Shalabh+K./26535923.html Thu, 21 May 2026 16:30:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Kenkare-Mitra+Sara/26535930.html si-local-file:///var/storage/secattach/20260521/26535930.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Kenkare-Mitra+Sara/26535930.html Thu, 21 May 2026 16:30:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Kenkare-Mitra+Sara/26535930.html si-local-file:///var/storage/secattach/20260521/26535930.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Kenkare-Mitra+Sara/26535930.html Thu, 21 May 2026 16:30:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Pramod/26528881.html si-local-file:///var/storage/secattach/20260520/26528881.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Pramod/26528881.html Wed, 20 May 2026 16:31:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Pramod/26528881.html si-local-file:///var/storage/secattach/20260520/26528881.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Gupta+Pramod/26528881.html Wed, 20 May 2026 16:31:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Townsend+John/26528882.html si-local-file:///var/storage/secattach/20260520/26528882.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Townsend+John/26528882.html Wed, 20 May 2026 16:31:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Townsend+John/26528882.html si-local-file:///var/storage/secattach/20260520/26528882.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Townsend+John/26528882.html Wed, 20 May 2026 16:31:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Jermasek+Douglas/26528890.html si-local-file:///var/storage/secattach/20260520/26528890.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Jermasek+Douglas/26528890.html Wed, 20 May 2026 16:31:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Jermasek+Douglas/26528890.html si-local-file:///var/storage/secattach/20260520/26528890.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Jermasek+Douglas/26528890.html Wed, 20 May 2026 16:31:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Laumas+Sandeep/26515724.html si-local-file:///var/storage/secattach/20260518/26515724.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Laumas+Sandeep/26515724.html Mon, 18 May 2026 20:58:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Laumas+Sandeep/26515724.html si-local-file:///var/storage/secattach/20260518/26515724.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Unicycive+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Laumas+Sandeep/26515724.html Mon, 18 May 2026 20:58:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unicycive+Therapeutics%2C++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26507240.html si-local-file:///var/storage/secattach/20260515/26507240.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unicycive+Therapeutics%2C++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26507240.html Fri, 15 May 2026 16:49:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unicycive+Therapeutics%2C++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26507240.html si-local-file:///var/storage/secattach/20260515/26507240.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unicycive+Therapeutics%2C++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26507240.html Fri, 15 May 2026 16:49:00 -0400 O.50789672 UNCY http://www.streetinsider.com/Analyst+PT+Change/Unicycive+Therapeutics+%28UNCY%29+PT+Lowered+to+%2437+at+Guggenheim/26481265.html (Updated - May 13, 2026 6:51 AM EDT) <p>Guggenheim analyst Vamil Divan lowered the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $37.00 (from $40.00) while maintaining a Buy rating.</p><p>The analyst commented: "UNCY released 1Q 2026 results and provided a corporate update earlier today that overall was in line with our expectations. Most importantly, the company continues to be on track for potential FDA approval of oxylanthanum carbonate (OLC) on its upcoming June 29th PDUFA, with commercial launch to follow after that, assuming approval. In our recent discussions with management, the team indicated that they are confident that manufacturing issues at http://www.streetinsider.com/Analyst+PT+Change/Unicycive+Therapeutics+%28UNCY%29+PT+Lowered+to+%2437+at+Guggenheim/26481265.html Wed, 13 May 2026 06:51:02 -0400 UNCY http://www.streetinsider.com/Analyst+Comments/Unicycive+Therapeutics+%28UNCY%29+PT+Lowered+to+%2437+at+Guggenheim/26481265.html (Updated - May 13, 2026 6:51 AM EDT) <p>Guggenheim analyst Vamil Divan lowered the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $37.00 (from $40.00) while maintaining a Buy rating.</p><p>The analyst commented: "UNCY released 1Q 2026 results and provided a corporate update earlier today that overall was in line with our expectations. Most importantly, the company continues to be on track for potential FDA approval of oxylanthanum carbonate (OLC) on its upcoming June 29th PDUFA, with commercial launch to follow after that, assuming approval. In our recent discussions with management, the team indicated that they are confident that manufacturing issues at http://www.streetinsider.com/Analyst+Comments/Unicycive+Therapeutics+%28UNCY%29+PT+Lowered+to+%2437+at+Guggenheim/26481265.html Wed, 13 May 2026 06:51:02 -0400 UNCY http://www.streetinsider.com/Earnings/Unicycive+Therapeutics%2C+Inc+%28UNCY%29+Misses+Q1+EPS+by+54c/26473469.html <p>Unicycive Therapeutics, Inc (NASDAQ: UNCY) reported Q1 EPS of ($0.54).</p><p>For earnings history and earnings-related data on Unicycive Therapeutics, Inc (UNCY) <a href="http://www.streetinsider.com/ec_earnings.php?q=UNCY">click here</a>.</p> http://www.streetinsider.com/Earnings/Unicycive+Therapeutics%2C+Inc+%28UNCY%29+Misses+Q1+EPS+by+54c/26473469.html Tue, 12 May 2026 08:05:12 -0400 UNCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unicycive+Therapeutics%2C+++For%3A+May+12/26473152.html si-local-file:///var/storage/secattach/20260512/26473152.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unicycive+Therapeutics%2C+++For%3A+May+12/26473152.html Tue, 12 May 2026 07:52:00 -0400 O.50789672 UNCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unicycive+Therapeutics%2C+++For%3A+May+12/26473152.html si-local-file:///var/storage/secattach/20260512/26473152.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unicycive+Therapeutics%2C+++For%3A+May+12/26473152.html Tue, 12 May 2026 07:52:00 -0400 O.50789672 UNCY http://www.streetinsider.com/Press+Releases/Unicycive+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26472863.html <ul><li style="text-align:center;"><em>U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026</em><br/></li><li style="list-style-position:inside; text-align:center;"><em>Commercial readiness activities continue in anticipation of the potential commercial launch of OLC</em><br/></li></ul> <p align="justify">MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update<em>. </em></p> <p align="justify">“As we http://www.streetinsider.com/Press+Releases/Unicycive+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26472863.html Tue, 12 May 2026 07:05:00 -0400 A.06822034 A.50216777 O.20026344 O.50789672 O.54516537 UNCY http://www.streetinsider.com/Press+Releases/Unicycive+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26472863.html <ul><li style="text-align:center;"><em>U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026</em><br/></li><li style="list-style-position:inside; text-align:center;"><em>Commercial readiness activities continue in anticipation of the potential commercial launch of OLC</em><br/></li></ul> <p align="justify">MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update<em>. </em></p> <p align="justify">“As we http://www.streetinsider.com/Press+Releases/Unicycive+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26472863.html Tue, 12 May 2026 07:05:00 -0400 A.06822034 A.50216777 O.20026344 O.50789672 O.54516537 UNCY http://www.streetinsider.com/Press+Releases/Unicycive+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26472863.html <ul><li style="text-align:center;"><em>U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026</em><br/></li><li style="list-style-position:inside; text-align:center;"><em>Commercial readiness activities continue in anticipation of the potential commercial launch of OLC</em><br/></li></ul> <p align="justify">MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update<em>. </em></p> <p align="justify">“As we http://www.streetinsider.com/Press+Releases/Unicycive+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26472863.html Tue, 12 May 2026 07:05:00 -0400 A.06822034 A.50216777 O.20026344 O.50789672 O.54516537 UNCY